Agilent Expands Tumor Profiling Portfolio with SureSelect Cancer Research Pan Heme

The new panel is for research use only, not for use in diagnostic procedures.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Integrated DNA and RNA profiling solution developed in collaboration with Roswell Park Comprehensive Cancer Center

SANTA CLARA, Calif.--(BUSINESS WIRE)-- Agilent Technologies Inc. (NYSE: A) today announced the SureSelect Cancer Research Pan Heme, a hybrid capture-based next-generation sequencing (NGS) research solution for comprehensive genomic profiling of hematologic malignancies. Developed in collaboration with experts at Roswell Park Comprehensive Cancer Center, the solution integrates DNA and RNA profiling, automated sample preparation and bioinformatics in a streamlined workflow.

The introduction of SureSelect Cancer Research Pan Heme expands Agilent’s tumor profiling portfolio for cancer research, providing a purpose-built solution for comprehensive profiling of hematologic tumors alongside SureSelect Cancer Research CGP for solid tumors and SureSelect Human All Exon V8 for ultra-comprehensive profiling for research across cancer types.

SureSelect Cancer Research Pan Heme interrogates 359 DNA genes and 124 RNA genes and assesses major classes of genomic alterations, including single-nucleotide variants (SNVs), insertions and deletions (indels), copy number variants (CNVs), IGH/IGK/IGL translocations and gene fusions. The solution combines Agilent SureSelect target enrichment technology with automated workflow options and integrated analysis capabilities.

“Researchers studying hematologic malignancies need comprehensive genomic information while also managing increasingly complex laboratory workflows,” said Majken Nielsen, vice president and general manager of Agilent's Clinical Diagnostics Division. “SureSelect Cancer Research Pan Heme brings together DNA and RNA profiling, walkaway automation and analysis in an integrated research workflow, helping laboratories generate deeper molecular insights while reducing hands-on demands and simplifying the path from sample to results.”

The panel was codeveloped with hematologic cancer experts at Roswell Park Comprehensive Cancer Center, whose expertise informed panel content curation and assay optimization. In Roswell Park’s current implementation, the integrated laboratory and informatics workflow supports sample-to-report results in approximately 48 hours.

“Hematologic malignancies are incredibly complex, and gaining a comprehensive view often requires looking at both DNA and RNA,” said Sean Glenn, Ph.D., vice chair of molecular pathology at Roswell Park Comprehensive Cancer Center. “We’ve been able to combat these limitations with Agilent to streamline comprehensive genomic profiling into an efficient automated workflow, providing insights in about 48 hours. We’re excited to see this workflow become available to researchers to help simplify and democratize a robust molecular profiling solution for hematologic cancer research.”

SureSelect Cancer Research Pan Heme can be paired with the Agilent Magnis NGS Prep System for fully automated library preparation and target enrichment. Magnis uses prefilled, cartridge-based reagents to simplify workflow setup and enables walkaway operation, allowing laboratories to extend processing into unattended and overnight hours. QIAGEN Clinical Insight (QCI) supports variant analysis and reporting. Manual and semiautomated configurations are also available to support different laboratory workflow and throughput requirements.

SureSelect Cancer Research Pan Heme is For Research Use Only. Not for use in diagnostic procedures.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.95 billion in fiscal year 2025 and employs approximately 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and Facebook.

View source version on businesswire.com: https://www.businesswire.com/news/home/20261110798330/en/

MEDIA CONTACTS:
Christian Colón
Agilent Technologies Inc.
+1 302-867-4117
christian.colon@agilent.com

Source: Agilent Technologies Inc.

Key Terms

next-generation sequencing technical

Next-generation sequencing is a set of laboratory techniques that read large amounts of DNA or RNA quickly and cheaply by processing millions of short genetic fragments in parallel, rather than one at a time. For investors, it matters because faster, lower-cost genetic data powers drug discovery, diagnostic tests and personalized medicine, creating scalable revenue opportunities and competitive advantages for companies that own the technology or services.

hybrid capture technical

A laboratory method for isolating and measuring specific DNA or RNA sequences by using short pieces of nucleic acid (probes) that bind (hybridize) to the target sequence; the probe–target complexes are then captured on a solid support or separated from non‑target material and the retained material is detected or sequenced. Hybrid capture is used both in diagnostic assays (to detect pathogens or biomarkers) and in next‑generation sequencing workflows (to enrich selected genomic regions) and depends on prior knowledge of the sequences to design the probes, so it may fail to recover targets with large unknown variations or sequences not covered by the probe set.

single-nucleotide variants medical

A single-nucleotide variant is a change in one “letter” of the DNA code at a specific position, like a single typo in a long instruction manual for building and operating cells. Investors care because these tiny changes can alter how a gene works, affect disease risk, or determine whether a drug or diagnostic test will work for certain patients, which influences the commercial potential and regulatory risk of biotech and healthcare investments.

indels medical

Indels are small insertions or deletions of DNA “letters” that add or remove genetic material and can change how a gene is read or how a protein functions. For investors, indels matter because they can alter disease mechanisms, affect the performance of diagnostics and therapies, and influence clinical trial outcomes, regulatory decisions and commercial value—imagine adding or removing words from a recipe that makes the dish turn out very different.

copy number variants medical

Copy number variants are places in a person’s DNA where stretches of genetic material are missing or duplicated, like pages removed from or copied extra in a manual for how a body works. These changes can affect how genes function and are commonly measured in genetic testing. Investors care because copy number variants drive demand for diagnostics, influence drug target selection and clinical trial outcomes, and can change the regulatory and market outlook for genetic tests and therapies.